Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Clinical Trial ID NCT01401504

Rank	Title	Journal	Year	PubWeight™‹?›
1	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	Clin Adv Hematol Oncol	2014	1.48
2	Novel ALK inhibitors in clinical use and development.	J Hematol Oncol	2015	1.24
3	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.	Onco Targets Ther	2014	1.19
4	Review of the current targeted therapies for non-small-cell lung cancer.	World J Clin Oncol	2014	1.05
5	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.	Front Oncol	2014	0.93
6	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.	Cancers (Basel)	2015	0.90
7	ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.	Ther Adv Med Oncol	2016	0.86
8	ALK Inhibitors, a Pharmaceutical Perspective.	Front Oncol	2012	0.82
9	The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.	Oncotarget	2014	0.82
10	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.	Dis Model Mech	2016	0.77
11	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.	Ther Adv Med Oncol	2015	0.76
12	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.	J Thorac Dis	2016	0.75